DK1924574T3 - Fremgangsmåde til syntese af 5-(methyl-1H-imidazol-1-yl)-3-(trifluormethyl)-benzenamin - Google Patents

Fremgangsmåde til syntese af 5-(methyl-1H-imidazol-1-yl)-3-(trifluormethyl)-benzenamin

Info

Publication number
DK1924574T3
DK1924574T3 DK06772448.4T DK06772448T DK1924574T3 DK 1924574 T3 DK1924574 T3 DK 1924574T3 DK 06772448 T DK06772448 T DK 06772448T DK 1924574 T3 DK1924574 T3 DK 1924574T3
Authority
DK
Denmark
Prior art keywords
benzenamine
imidazol
trifluoromethyl
synthesis
methyl
Prior art date
Application number
DK06772448.4T
Other languages
Danish (da)
English (en)
Inventor
Joseph Mckenna
Wen-Chung Shieh
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1924574T3 publication Critical patent/DK1924574T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)
DK06772448.4T 2005-06-09 2006-06-07 Fremgangsmåde til syntese af 5-(methyl-1H-imidazol-1-yl)-3-(trifluormethyl)-benzenamin DK1924574T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68897705P 2005-06-09 2005-06-09
US70559005P 2005-08-04 2005-08-04
PCT/US2006/022155 WO2006135641A2 (en) 2005-06-09 2006-06-07 PROCESS FOR THE SYNTHESIS OF 5- (METHYL-lH-IMIDAZOL-l-YL) -3- (TRI FLUOROME TH YL) -BENZENEAMINE

Publications (1)

Publication Number Publication Date
DK1924574T3 true DK1924574T3 (da) 2011-02-14

Family

ID=37091153

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06772448.4T DK1924574T3 (da) 2005-06-09 2006-06-07 Fremgangsmåde til syntese af 5-(methyl-1H-imidazol-1-yl)-3-(trifluormethyl)-benzenamin

Country Status (31)

Country Link
US (2) US8124763B2 (enExample)
EP (1) EP1924574B1 (enExample)
JP (1) JP5118024B2 (enExample)
KR (3) KR20120066067A (enExample)
AR (1) AR053890A1 (enExample)
AT (1) ATE487709T1 (enExample)
AU (1) AU2006258051B2 (enExample)
BR (1) BRPI0611663A2 (enExample)
CA (1) CA2610105C (enExample)
CY (1) CY1111428T1 (enExample)
DE (1) DE602006018156D1 (enExample)
DK (1) DK1924574T3 (enExample)
EC (1) ECSP077982A (enExample)
EG (1) EG25039A (enExample)
GT (1) GT200600217A (enExample)
IL (1) IL187421A (enExample)
JO (1) JO2636B1 (enExample)
MA (1) MA29599B1 (enExample)
MX (1) MX2007015423A (enExample)
MY (1) MY147436A (enExample)
NO (1) NO340743B1 (enExample)
NZ (1) NZ563740A (enExample)
PE (1) PE20070015A1 (enExample)
PL (1) PL1924574T3 (enExample)
PT (1) PT1924574E (enExample)
RU (1) RU2444520C2 (enExample)
SA (1) SA06270147B1 (enExample)
SI (1) SI1924574T1 (enExample)
TN (1) TNSN07463A1 (enExample)
TW (1) TWI430999B (enExample)
WO (1) WO2006135641A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
TWI433677B (zh) 2007-06-04 2014-04-11 Avila Therapeutics Inc 雜環化合物及其用途
US20100016590A1 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
EP2530081A3 (en) 2008-11-05 2013-04-10 Teva Pharmaceutical Industries, Ltd. Nilotinib HCI crystalline forms
WO2010060074A1 (en) * 2008-11-24 2010-05-27 Teva Pharmaceutical Industries Ltd. Preparation of nilotinib and intermediates thereof
US20110053968A1 (en) 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
WO2012135651A1 (en) 2011-03-31 2012-10-04 The Procter & Gamble Company Systems, models and methods for identifying and evaluating skin-active agents effective for treating dandruff/seborrheic dermatitis
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
WO2013120852A1 (en) 2012-02-13 2013-08-22 Grindeks, A Joint Stock Company Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
US9920357B2 (en) 2012-06-06 2018-03-20 The Procter & Gamble Company Systems and methods for identifying cosmetic agents for hair/scalp care compositions
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
CN103694176B (zh) 2014-01-07 2015-02-18 苏州立新制药有限公司 尼洛替尼中间体的制备方法
EP3095782A1 (en) 2015-05-18 2016-11-23 Esteve Química, S.A. New method for preparing 3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)benzenamine
EP3749697A4 (en) 2018-02-05 2021-11-03 Bio-Rad Laboratories, Inc. CHROMATOGRAPHY RESIN WITH LIGAND MIXED MODE ANIONIC / HYDROPHOBIC EXCHANGE
EP3806858A4 (en) 2018-06-15 2022-03-09 Handa Pharmaceuticals, Inc. KINA INHIBITOR SALTS AND COMPOSITIONS THEREOF
JP2020007240A (ja) * 2018-07-04 2020-01-16 住友化学株式会社 ベンズアミド化合物の製造方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136082A (en) * 1990-08-03 1992-08-04 Himont Incorporated Process for preparing organic esters and amides and catalyst system therefor
AU5539294A (en) 1992-12-24 1994-07-19 Hemagen/Pfc Fluorocarbon emulsions
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5597829A (en) 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6323366B1 (en) 1997-07-29 2001-11-27 Massachusetts Institute Of Technology Arylamine synthesis
AR013261A1 (es) 1997-08-01 2000-12-13 Smithkline Beecham Corp Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina
US20030059465A1 (en) 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
US6395916B1 (en) * 1998-07-10 2002-05-28 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
EP1044977B1 (en) 1999-03-09 2002-05-02 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Camptothecin derivatives having antitumor activity
IT1306129B1 (it) 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
DE19926056B4 (de) 1999-06-08 2004-03-25 Gkss-Forschungszentrum Geesthacht Gmbh Einrichtung zur Analyse atomarer und/oder molekularer Elemente mittels wellenlängendispersiver, röntgenspektrometrischer Einrichtungen
GB9918885D0 (en) 1999-08-10 1999-10-13 Pharmacia & Upjohn Spa Pharmaceutical formulations in hydroxypropymethycellulose capsules
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US20040009229A1 (en) 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
US20020150615A1 (en) 2001-02-12 2002-10-17 Howard Sands Injectable pharmaceutical composition comprising microdroplets of a camptothecin
US6629598B2 (en) 2001-08-10 2003-10-07 Vinod K. Narula Flexible ribbed splint system
US6653319B1 (en) 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues
WO2003032906A2 (en) 2001-10-15 2003-04-24 Crititech, Inc. Delivery of poorly soluble drugs
AU2002353118A1 (en) 2001-12-11 2003-07-24 Dor Biopharma, Inc. Lipid particles and suspensions and uses thereof
JP2003267891A (ja) 2002-03-13 2003-09-25 Mitsubishi-Kagaku Foods Corp W/o/w型エマルション製剤
FR2840303B1 (fr) * 2002-05-31 2005-07-15 Rhodia Chimie Sa Procede d'arylation ou de vinylation ou d'alcylynation d'un compose nucleophile
CZ294371B6 (cs) 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
EP1393719A1 (en) 2002-08-23 2004-03-03 Munich Biotech AG Camptothecin-carboxylate formulations
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
JP4426749B2 (ja) 2002-07-11 2010-03-03 株式会社産学連携機構九州 O/w型エマルション製剤
US20040171560A1 (en) 2002-12-23 2004-09-02 Dabur Research Foundation Stabilized pharmaceutical composition
JP2006199590A (ja) 2003-09-04 2006-08-03 Nano Career Kk 水溶性の塩基性薬物内包ナノ粒子含有組成物
CA2543722C (en) 2003-10-29 2011-01-04 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
CA2548078C (en) 2003-12-17 2009-05-12 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of camptothecins and process for making same
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos

Also Published As

Publication number Publication date
RU2444520C2 (ru) 2012-03-10
HK1117524A1 (en) 2009-01-16
AU2006258051A1 (en) 2006-12-21
JP5118024B2 (ja) 2013-01-16
IL187421A (en) 2011-11-30
MX2007015423A (es) 2008-02-21
PL1924574T3 (pl) 2011-04-29
TNSN07463A1 (en) 2009-03-17
NO340743B1 (no) 2017-06-12
KR20130118394A (ko) 2013-10-29
IL187421A0 (en) 2008-02-09
US8124763B2 (en) 2012-02-28
CY1111428T1 (el) 2015-08-05
SI1924574T1 (sl) 2011-02-28
PT1924574E (pt) 2011-02-08
KR20120066067A (ko) 2012-06-21
TWI430999B (zh) 2014-03-21
EG25039A (en) 2011-07-06
US8946416B2 (en) 2015-02-03
EP1924574B1 (en) 2010-11-10
KR20080022093A (ko) 2008-03-10
MY147436A (en) 2012-12-14
AU2006258051B2 (en) 2010-09-09
US20080188656A1 (en) 2008-08-07
CA2610105C (en) 2014-03-25
JO2636B1 (en) 2012-06-17
ATE487709T1 (de) 2010-11-15
JP2008545786A (ja) 2008-12-18
NO20080157L (no) 2008-01-09
CA2610105A1 (en) 2006-12-21
EP1924574A2 (en) 2008-05-28
SA06270147B1 (ar) 2009-12-22
TW200726756A (en) 2007-07-16
MA29599B1 (fr) 2008-07-01
AR053890A1 (es) 2007-05-23
PE20070015A1 (es) 2007-02-06
GT200600217A (es) 2007-03-28
ECSP077982A (es) 2008-01-23
NZ563740A (en) 2011-03-31
KR101216249B1 (ko) 2012-12-28
US20120116081A1 (en) 2012-05-10
WO2006135641A2 (en) 2006-12-21
DE602006018156D1 (de) 2010-12-23
BRPI0611663A2 (pt) 2010-09-28
RU2007148231A (ru) 2009-07-20
KR101514593B1 (ko) 2015-04-22
WO2006135641A3 (en) 2007-03-29

Similar Documents

Publication Publication Date Title
IL284991A (en) Antibodies against cd38 for treatment of multiple myeloma
DK1924574T3 (da) Fremgangsmåde til syntese af 5-(methyl-1H-imidazol-1-yl)-3-(trifluormethyl)-benzenamin
DK1795576T3 (da) Fremgangsmåde til fremstilling af carbonhydrider
DK2292607T3 (da) Fremgangsmåde til syntese af organiske forbindelser
DK1893586T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1778668T3 (da) Fremgangsmåde til fremstilling af dihydropteridion
DK2423325T3 (da) Fremgangsmåde til fremstilling af biblioteker af template-polynukleotider
DK2431359T3 (da) Fremgangsmåde til fremstilling af diaminophenothiaziniumforbindelser
DK2781593T3 (da) Fremgangsmåde til behandling af methanemissioner
CY2014029I1 (el) Ισοξαζολινες για τον ελεγχο ασπονδυλων παρασιτων
DK2207779T3 (da) Fremgangsmåde til syntese af morpholinooligomerer
DK2824183T3 (da) Fremgangsmåde til fremstilling af bispecifikke antistoffer
IL198186A (en) Mphosph1 derived peptide vaccines
DK3336073T3 (da) Fremgangsmåde til fremstilling af fluorerede organiske forbindelser
DK3056568T3 (da) Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
DK1651622T3 (da) Fremgangsmåde til fremstilling af 2-(quinoxalin-5-ylsulfonylamino)-benzamidforbindelser
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet
DK1948176T3 (da) Diarylurinstoffer til behandling af pulmonær hypertension
DK1937650T3 (da) Heterocykliske forbindelser
DK1947933T4 (da) System til styret udbringning af herbicider
PL1896425T3 (pl) Sposób wytwarzania 5-(metylo-1H-1-ilo)-3-trifluorometylo)-benzenoaminy
DK1881830T3 (da) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinolin-derivater til behandling af infertilitet
DK1831223T3 (da) Fremgangsmåde til fremstilling af L-biopterin
DK2366393T3 (da) Roflumilast til behandlingen af pulmonal hypertension